Fragmented Particles Containing Octreotide Acetate Prepared by Spray Drying Technique for Dry Powder Inhalation

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2018 Mar 31

PMID 29600480

Citations 5

Authors

Ailin Hou

Lu Li

Ying Huang

Vikramjeet Singh

Chune Zhu

Xin Pan

Guilan Quan

Chuanbin Wu

Affiliations

Soon will be listed here.

Abstract

Dry powder inhalers (DPIs) have been proposed as an alternative administration route for protein and peptide drugs. However, DPI particles are easy to aggregate due to the strong interactions between the particles, leading to poor aerosolization performance. In this study, fragmented particles containing octreotide acetate (OA) were prepared by spray drying technique for dry powder inhalation, which were expected to decrease the particle-particle interaction by reducing the contact sites. Mannitol and ammonium carbonate were used as protein stabilizer and fragment-forming agent, respectively. The obtained fragmented particles presented larger particle size, lower density, better dispersibility, and well in vitro aerodynamic behavior (emitted dose > 97%, fine particle fraction ≈ 40%). The circular dichroism spectrum results indicated that OA maintained the stability throughout the spray drying process. The relative bioavailability of dry powder inhalation (DPI) compared with subcutaneous injection of commercial product was up to 88.0%, demonstrating the feasibility of DPI for OA delivery. These results confirmed that the proposed fragmented particles had great potential for pulmonary delivery of protein and peptide drugs in a painless, rapid, and convenient manner.

Citing Articles

Engineering Inhalable Therapeutic Particles: Conventional and Emerging Approaches.

Negi A, Nimbkar S, Moses J Pharmaceutics. 2023; 15(12).

PMID: 38140047 PMC: 10748168. DOI: 10.3390/pharmaceutics15122706.

Spray-Dried Inhalable Powder Formulations of Therapeutic Proteins and Peptides.

Eedara B, Alabsi W, Encinas-Basurto D, Polt R, Mansour H AAPS PharmSciTech. 2021; 22(5):185.

PMID: 34143327 DOI: 10.1208/s12249-021-02043-5.

Dry Powder for Pulmonary Delivery: A Comprehensive Review.

Chaurasiya B, Zhao Y Pharmaceutics. 2020; 13(1).

PMID: 33379136 PMC: 7824629. DOI: 10.3390/pharmaceutics13010031.

A homogenous nanoporous pulmonary drug delivery system based on metal-organic frameworks with fine aerosolization performance and good compatibility.

Zhou Y, Niu B, Wu B, Luo S, Fu J, Zhao Y Acta Pharm Sin B. 2020; 10(12):2404-2416.

PMID: 33354510 PMC: 7745127. DOI: 10.1016/j.apsb.2020.07.018.

Preparation of an oil suspension containing ondansetron hydrochloride as a sustained release parenteral formulation.

Nguyen T, Duong V, Maeng H, Chi S Drug Deliv Transl Res. 2019; 10(1):282-295.

PMID: 31659599 DOI: 10.1007/s13346-019-00687-2.

References

Katz M, Erstad B . Octreotide, a new somatostatin analogue. Clin Pharm. 1989; 8(4):255-73. View

Peng J, Qi X, Chen Y, Ma N, Zhang Z, Xing J . Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells. J Drug Target. 2014; 22(5):428-38. DOI: 10.3109/1061186X.2013.879386. View

Azkur D, Yoldas T, Toyran M, Kocabas C . A pediatric case of anaphylaxis due to octreotide. Asian Pac J Allergy Immunol. 2012; 29(4):361-3. View

Maggio E, Grasso P . Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. Regul Pept. 2011; 167(2-3):233-8. DOI: 10.1016/j.regpep.2011.02.009. View

Lerner E, van Zanten E, Stewart G . Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration. J Drug Target. 2004; 12(5):273-80. DOI: 10.1080/10611860400000938. View

Schuetz Y, Naik A, Guy R, Kalia Y . Effect of amino acid sequence on transdermal iontophoretic peptide delivery. Eur J Pharm Sci. 2005; 26(5):429-37. DOI: 10.1016/j.ejps.2005.07.012. View

Tug T, Kara H, Karaoglu A, Karatas F, Turgut N, Ayan E . The effect of octreotide, an analog of somatostatin, on bleomycin-induced interstitial pulmonary fibrosis in rats. Drug Chem Toxicol. 2012; 36(2):181-6. DOI: 10.3109/01480545.2012.710618. View

Dua K, Hansbro N, Foster P, Hansbro P . MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases. Drug Deliv Transl Res. 2016; 7(1):168-178. DOI: 10.1007/s13346-016-0343-6. View

Salama R, Young P, Traini D . Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline. Drug Deliv Transl Res. 2015; 4(3):256-67. DOI: 10.1007/s13346-013-0137-z. View

10.

Saboti D, Maver U, Chan H, Planinsek O . Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying. J Pharm Sci. 2017; 106(7):1881-1888. DOI: 10.1016/j.xphs.2017.02.035. View

11.

Chow A, Tong H, Chattopadhyay P, Shekunov B . Particle engineering for pulmonary drug delivery. Pharm Res. 2007; 24(3):411-37. DOI: 10.1007/s11095-006-9174-3. View

12.

Sung J, Pulliam B, Edwards D . Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007; 25(12):563-70. DOI: 10.1016/j.tibtech.2007.09.005. View

13.

Tewes F, Paluch K, Tajber L, Gulati K, Kalantri D, Ehrhardt C . Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery. Eur J Pharm Biopharm. 2013; 85(3 Pt A):604-13. DOI: 10.1016/j.ejpb.2013.03.020. View

14.

Peng T, Zhang X, Huang Y, Zhao Z, Liao Q, Xu J . Nanoporous mannitol carrier prepared by non-organic solvent spray drying technique to enhance the aerosolization performance for dry powder inhalation. Sci Rep. 2017; 7:46517. PMC: 5411962. DOI: 10.1038/srep46517. View

15.

Bivas-Benita M, Zwier R, Junginger H, Borchard G . Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm. 2005; 61(3):214-8. DOI: 10.1016/j.ejpb.2005.04.009. View

16.

Traini D, Young P, Rogueda P, Price R . In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers. Pharm Res. 2006; 24(1):125-35. DOI: 10.1007/s11095-006-9130-2. View

17.

Nolan L, Tajber L, McDonald B, Barham A, Corrigan O, Healy A . Excipient-free nanoporous microparticles of budesonide for pulmonary delivery. Eur J Pharm Sci. 2009; 37(5):593-602. DOI: 10.1016/j.ejps.2009.05.007. View

18.

Kwok P, Chan H . Effect of relative humidity on the electrostatic charge properties of dry powder inhaler aerosols. Pharm Res. 2007; 25(2):277-88. DOI: 10.1007/s11095-007-9377-2. View

19.

Mishra D, Dhote V, Bhargava A, Jain D, Mishra P . Amorphous solid dispersion technique for improved drug delivery: basics to clinical applications. Drug Deliv Transl Res. 2015; 5(6):552-65. DOI: 10.1007/s13346-015-0256-9. View

20.

Monckedieck M, Kamplade J, Fakner P, Urbanetz N, Walzel P, Steckel H . Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate. Int J Pharm. 2017; 524(1-2):351-363. DOI: 10.1016/j.ijpharm.2017.03.055. View